The MRC Randomised-controlled Trial of Interferon-α, Interleukin-2 and 5-Fluorouracil vs Interferon-α Alone in Patients with Advanced Renal cell Carcinoma (RE04): Rationale and Progress

ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma

Immunochemotherapy for Metastatic Renal Cell Carcinoma Using a Regimen of Interleukin-2, Interferon-alpha and 5-fluorouracil

Renal cell carcinoma: translational aspects of metabolism and therapeutic consequences

Kidney cancer: Identification of novel targets for therapy

Focus on kidney cancer

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Solid Renal Masses in Transplanted Allograft Kidneys: A Closer Look at the Epidemiology and Management.

Renal Cell Carcinoma: Diagnosis Based on Metastatic Manifestations

C-REACTIVE PROTEIN: A BIOMARKER OF SURVIVAL IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH SUBCUTANEOUS INTERLEUKIN-2 BASED IMMUNOTHERAPY

Chronic Kidney Disease in Patients With Renal Cell Carcinoma

Improving Consistency and Quality of Care for Older Adults With Cancer: The Challenges of Developing Consensus Guidelines for Radiation Therapy

Is there a role for novel TKI/ICI combinations in metastatic renal cell carcinoma? Definitely maybe

The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO)

Ultrahypofractionation Should be a Standard of Care Option for Intermediate-Risk Prostate Cancer